- Home
- BORR vs INVA Comparison
BORR vs INVA Comparison
Compare BORR & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$21.92
Company Overview
Basic Information| Metric | BORR | INVA |
|---|---|---|
| Founded | 2016 | 1996 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2017 | 2000 |
Fundamental Metrics
Financial Performance| Metric | BORR | INVA |
|---|---|---|
| Price | $5.05 | $21.92 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 5 |
| Target Price | $6.25 | ★ $32.80 |
| AVG Volume (30 Days) | ★ 7.1M | 592.5K |
| Earning Date | 02-18-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 816.67 |
| EPS | N/A | ★ 3.30 |
| Revenue | N/A | ★ $217,217,000.00 |
| Revenue This Year | $4.23 | $8.95 |
| Revenue Next Year | $22.09 | $12.65 |
| P/E Ratio | $20.64 | ★ $6.57 |
| Revenue Growth | N/A | ★ 62.63 |
| 52 Week Low | $1.55 | $16.52 |
| 52 Week High | $6.25 | $25.15 |
Technical Indicators
Market Signals| Indicator | BORR | INVA |
|---|---|---|
| Relative Strength Index (RSI) | 44.81 | 46.80 |
| Support Level | $3.72 | $20.56 |
| Resistance Level | $6.25 | $21.99 |
| Average True Range (ATR) | 0.29 | 0.51 |
| MACD | -0.11 | -0.14 |
| Stochastic Oscillator | 30.19 | 22.31 |
Price Performance
Historical Comparison BORR
INVA
About BORR Borr Drilling Limited
Borr Drilling Ltd is a drilling contractor that owns and operates jack-up rigs of modern and high-specification designs providing drilling services to the oil and gas exploration and production industry. The company operates a fleet of around 16 jack-up drilling rigs. Geographically the activities are carried out through Norway.
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.